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Aim: Epigenetic changes may occur in response to environmental stressors, and 
an altered epigenome pattern may represent a stable signature of environmental 
exposure. Materials & methods: Here, we examined the potential of DNA methylation 
changes in 910 prediagnostic peripheral blood samples as a marker of exposure to 
tobacco smoke in a large multinational cohort. Results: We identified 748 CpG sites 
that were differentially methylated between smokers and nonsmokers, among 
which we identified novel regionally clustered CpGs associated with active smoking. 
Importantly, we found a marked reversibility of methylation changes after smoking 
cessation, although specific genes remained differentially methylated up to 22 years 
after cessation. Conclusion: Our study has comprehensively cataloged the smoking-
associated DNA methylation alterations and showed that these alterations are 
reversible after smoking cessation.
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Published online: 11 February 2016
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Smoking is a leading cause of morbidity and 
mortality worldwide. Among middle-aged 
people, tobacco use is estimated to be the 
most important preventable risk factor for 
premature death in men and the second most 
important risk factor in women (after high 
blood pressure) [1]. Tobacco-related mortality 
is set to increase to almost 1 billion deaths 
during the 21st century, most of them in 
low-income countries [2]. This calls not only 
for addressing primary prevention by reduc-
ing tobacco consumption but also for active 
secondary prevention by actively following 
up current and former smokers. Smoking 
contributes toward disease development and 
progression through genetic and epigen-
etic mechanisms [3]. Epigenetic mechanisms 
broadly include DNA methylation, histone 
modification and noncoding RNAs, [4], 
and previous studies implicated exposure to 
tobacco smoking in deregulation of these 
mechanisms.
Due to their plastic nature, DNA methyla-
tion patterns are suspected to be under the 
influence of aging, environmental, lifestyle 
and demographic factors [4–7]. The malleable 
nature of DNA methylation has been increas-
ingly exploited in biomarker discovery and 
mechanistic studies aimed at understanding 
constitutive and environmentally induced 
cancer risk [4,6,8–9]. A number of novel 
smoking-associated blood DNA methylation 
biomarkers have been identified using the 
Illumina 27K array [10,11] and more recently 
using the Illumina Infinium HumanMeth-
ylation 450K BeadChip array in cord blood 
and adult blood [12–16]. Among these mark-
ers, seven CpGs (F2RL3 [cg03636183], 
AHRR [cg21161138 and cg05575921], 2q37.1 
[cg21566642, cg01940273 and cg05951221] 
and 6p21.33 [cg06126421]) were common 
among most differentially methylated sites.
Previously published studies on smoking-
associated methylation changes have been 
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limited by sample size and/or DNA methylome cov-
erage. Moreover, all the studies focused on individual 
site-wise DNA methylation analysis associated with 
smoking, which provides useful information about 
the impact of smoking on specific CpG sites (differ-
entially methylated probes [DMPs]). However, CpGs 
can be highly correlated by function and genomic den-
sity, unlike SNPS in genome-wide association studies 
(GWAS). Therefore, dimension reduction approaches 
that identify highly correlated CpG clusters have 
become crucial and have been applied in this study, 
leading to the identification of differentially methyl-
ated regional clusters (DMRs) [16]. Another way to 
measure the impact of smoking on the DNA methy-
lome is to measure the methylome variability (most 
variable probe [MVP]), which has been shown to 
contribute to the observed differences in response to 
environmental agents and drugs [17].
None of the previous studies have documented 
dimension reduction or MVP analyses when studying 
alterations in DNA methylation due to smoking expo-
sure. The present study was conducted in a case–con-
trol study on breast cancer nested within the European 
Prospective Investigation into Cancer and Nutrition 
(EPIC) cohort [18]. Furthermore, this longitudinal 
analysis of former smokers has enabled us to iden-
tify CpG sites that remain differentially methylated 
for more than a decade after smoking cessation. Our 
results not only validated the previously reported find-
ings in a large number of baseline blood samples from 
cohort participants but also identified novel markers as 
well as CpG clusters that respond to smoking exposure 
in a highly correlative manner.
Materials & methods
Study population
This study is based on the cohort of the European 
Prospective Investigation into Cancer and Nutri-
tion (EPIC), a large prospective study conducted in 
23 centers across ten European countries (Denmark, 
France, Germany, Greece, Italy, Norway, Spain, Swe-
den, the Netherlands and UK), aiming to investigate 
the relationship between diet, lifestyle, metabolism 
and cancer risk [19]. In brief, the EPIC cohort includes 
about 315,000 women and 200,000 men. At baseline 
recruitment, all study participants provided extensive 
questionnaire information about nutrition and other 
lifestyle factors. All study participants also provided 
a blood sample, which was processed, divided into 
aliquots of plasma, serum and buffy coat, and fro-
zen at -196°C (in liquid nitrogen) for later use in spe-
cific research projects. All participants gave written 
informed consent. The study was approved by the local 
ethics committees and the Institutional Review Board 
of the International Agency for Research on Cancer 
(IARC, Lyon, France).
Selection of participants
For the purpose of this study, we included 960 women 
from the EPIC-nested breast cancer case–control 
study. The matching criteria for the selection of the 
controls were: center, date of blood collection, age at 
blood collection, menopausal status, current use of the 
contraceptive pill and current use of hormone replace-
ment therapy. The set of 960 samples included 20 tech-
nical replicates to compare inter- and intra-array batch 
variation. The technical replicates and 30 samples that 
did not pass the quality control filters were excluded 
from the final analyses, leaving 910 participants (460 
controls and 450 cases). Smoking history included self-
reported current smoking status, number of cigarettes 
smoked per day and time since smoking cessation (for 
former smokers). Current smokers, never-smokers and 
former smokers were defined as subjects self-reporting 
current smoking, lifelong nonsmokers and ex-smokers, 
respectively. Total lifetime dosage of tobacco smoke 
was measured in pack-years (PY) as per the following 
formula (assuming 20 cigarettes per pack):
PY = (dose rate [cigarettes per day]/20) × number 
of years smoked
Bisulfite conversion & genome-wide DNA 
methylation analysis
DNA was isolated from the white blood cells as per 
the standard DNA extraction procedure (Autopure LS, 
Qiagen). DNA methylome profiling was carried out 
using the Illumina Infinium HumanMethylation450K 
(HM450K) BeadChip assay, which interrogates more 
than 480,000 methylation sites [20], essentially as 
described previously [21,22].
Bioinformatics analyses
Data preprocessing and analyses were performed using 
R (version 3.2.2)/Bioconductor packages. The DNA 
methylation level is described as the β-value, which 
is a continuous variable ranging between 0 (no meth-
ylation) and 1 (full methylation). To avoid spurious 
associations, we excluded the cross-reactive probes and 
probes overlapping with a known SNP with minor 
allele frequency of ≥5% in the overall population 
(European ancestry; [23]), leaving 423,066 probes. In 
any given sample, a probe with a detection p-value (a 
measure of an individual probe’s performance) ≥0.05 
was assigned ‘missing’ status. If a probe was missing in 
greater than 5% of samples, it was excluded from all 
samples. Thus, we excluded 1625 probes on this basis. 
Finally, 421,441 probes were available for the analyses, 
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which were corrected for probe color bias and inters-
ample quantile normalization, followed by β-mixture 
quantile normalization (BMIQ) to align type I and 
type II probe distributions [24]. We used the array 
annotations from the Bioconductor package FDb.
InfiniumMethylation.hg19 (version 2.2.0) to assign 
probes to their nearest corresponding genes.
Estimates of white blood cell counts
Quantile-normalized data were used to infer blood cell 
proportions (CD8+ T cells, CD4+ T cells, natural killer 
[NK] cells, B cells, monocytes and granulocytes) using 
Houseman’s estimation method [25,26], which is based 
on DNA methylation signatures from the purified 
leukocyte samples.
Statistical analyses
Identification of DMPs
Logarithmically transformed methylation values [27] 
were batch-corrected using surrogate variable analysis 
(SVA) [28] and interrogated for association with smok-
ing status (never vs current, former vs current and 
never vs former) by modeling the study variables and 
covariates (i.e., case–control status, age at blood col-
lection, menopausal status, current use of the contra-
ceptive pill and current use of hormone replacement 
therapy) together with latent surrogate variables by 
multivariable linear regression using the R/Biocon-
ductor package limma [29]. Smoking status associated 
loci were selected based on a threshold for the adjusted 
p-value (false discovery rate [FDR]) of 0.05 [30].
Identification of DMRs
The bump hunting method [25] was used to identify 
predefined regional clusters of neighboring CpGs that 
are differentially methylated with smoking status using 
the recommended proximity-based criteria [31]. We fit-
ted the linear model of methylation levels at each probe 
as a function of smoking status, adjusting for study 
variables and surrogate variables estimated by SVA. 
The family-wise error rate (FWER) for each DMR 
was estimated based on 1000 bootstraps under the null 
hypothesis.
Identification of MVPs
Sample-to-sample variability of DNA methylation at 
specific genomic locations captures the intersample 
variability, which distinguishes it from more com-
monly used mean methylation comparisons such as the 
DMP analysis. This intersample variability has previ-
ously been shown to be important for the identification 
of cancer-associated genes [32]. Differential variability 
between never-smokers and current smokers was iden-
tified using the DiffVar function implemented in the 
Bioconductor package missMethyl [33]. This function 
uses an empirical Bayes model framework to detect 
variability. The default criteria implemented in the 
package were used, except for the fact that latent vari-
ables identified through SVA were adjusted for in the 
model along with the covariates used for identifying 
differentially variable probes.
Pathway analysis
For the pathway analysis, we used 748 CpG sites found 
to be differentially methylated between never-smokers 
and current smokers. Pathway analysis methods devel-
oped for gene expression studies give false results when 
used for analysis of 450k array data where the number 
of sites in each gene range from single digits to greater 
than 1000 [34]. In order to circumvent this problem, we 
first corrected the significant CpG sites for the number 
of probes present on 450k array followed by FDR cor-
rection for the number of gene symbols in Illumina 
450k arrays. By doing this, we corrected for the identi-
fication of genes which have more probes on the 450k 
array and may potentially bias the pathway analysis. 
Thus, we had 538 genes for the pathway analysis, 
which was performed using Enrichr [35].
Results
Characteristics of the study population
To determine the differences in the DNA methylome 
between subjects who smoke and nonsmokers, we 
performed genome-wide DNA methylation profiling 
of baseline blood samples from cases and controls of 
the cohort-nested breast cancer case–control study. At 
baseline recruitment (time of blood collection), all sub-
jects were aged 26.1–72.8 years, with an average age 
of 52.4 years. Based on self-reported smoking status, 
the samples were divided into never-smokers, former 
smokers and current smokers. The general character-
istics of the participants are shown in Table 1. The 
proportion of premenopausal women was greater in 
current smokers compared with the other two catego-
ries. Based on our DNA methylation based estimates 
of the leukocyte subpopulations, current smokers 
had a slightly lower proportion of natural killer cells 
compared with the other two categories (p < 0.001) 
(Supplementary Figure 1).
Differentially methylated CpG probes in 
response to smoking: DMP analysis
Differentially methylated probe (DMP) analysis 
identified a total of 748 CpG sites that were differ-
entially methylated between current smokers and 
never-smokers (FDR ≤ 0.05). This included 450 
hypomethylated and 298 hypermethylated CpG sites 
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(Supplementary Table 1). The chromosome-wide dis-
tribution of significant CpG sites and their relevance is 
shown in Figure 1. Chromosome 5p and chromosome 
2q showed a number of significant probes associated 
with smoking exposure. Including BMI, alcohol con-
sumption and leukocyte subtypes in the model did 
not affect the main findings, and most of the CpG 
sites remained unchanged (Supplementary Figure 2). 
We therefore used the model without BMI, alcohol 
consumption and leukocyte subtypes for all future 
analyses.
The top five hypermethylated and the top five hypo-
methylated CpGs in current smokers versus never-
smokers with ≥5% difference in the methylation 
between these two categories are shown in Table 2. 
Some of the differentially methylated sites (AHRR, 
ALPPL2, F2RL3, GFI, GNG12, MYO1G, ZNF385D 
and CACNA1D) were identical to those identified in 
previous studies [12–16], demonstrating the reliabil-
ity and robustness of our analysis pipeline. In addi-
tion, we identified 12 novel CpG sites [cg22472290 
(ZNF577), cg16071219 (LPAR6 ), cg00008629 
(PTBP3), cg04224247 (WWC3), cg24874254 
(PRDM1), cg24134897 (TSPAN4), cg02610360 
(TMEM136 ), cg19925780 (DPH5), cg05156137 
(RCAN1), cg04387347 (MIR5189), cg01899620 
(MCF2L) and cg11028075 (SORBS1)] associated 
with smoking (Table 3). All of these CpG sites had 
≥3% methylation difference between current smokers 
and never-smokers. Two of those sites, cg24134897 
(TSPAN4) and cg05156137 (RCAN1), were also dif-
ferentially methylated in current smokers relative to 
former smokers (≥2% difference). More than 90% of 
the DMPs in current smokers versus never-smokers 
were replicated in the comparison of current smokers 
versus former smokers. All the DMPs that were differ-
ent between current and former smokers are shown in 
Supplementary Table 2. A similar DMP analysis com-
paring never and former smokers revealed four CpG 
sites shown in Supplementary Table 4.
An enrichment analysis for the functional distribu-
tion of significant smoking-associated CpG sites (n = 
748) revealed an enrichment for open seas (regions 
containing isolated CpG sites in the genome that do 
not have a specific designation) and lower representa-
tion of the CpG islands, while the adjacent regions 
of CpG islands, such as the shores (0–2 kb from the 
promoter CpG islands) and shelves (2–4 kb from the 
promoter CpG islands) had an expected representa-
tion (data not shown) (Figure 2A). We found that 
there was a decrease in the promoter-related sites in 
the DMPs compared with the Illumina 450K array 
(Figure 2B). We observed a significant enrichment 
in the regulation of cell activation (GO: 0050865), 
while pathway analysis using the KEGG pathway 
revealed chronic myeloid leukemia, melanoma, hema-
topoietic cell lineage, regulation of actin cytoskeleton 
and glioma (Supplementary Figure 3).
Table 1. Clinical characteristics of participants who passed the quality control filters of the Illumina 450K array.
Characteristic All subjects  
(n = 910)
Never-smokers  
(n = 528)
Former smokers 
(n = 189)
Current smokers 
(n = 193)
p-value
Cases:controls 450:460 263:265 96:93 91:102 p = 0.75† 
Age (years) 52.4 ± 8.8 54.0 ± 8.5 51.6 ± 8.9 48.6 ± 8.8 p < 0.001‡
BMI (kg/m2) 25.8 ± 4.4 26.2 ± 4.3 25.5 ± 4.7 24.8 ± 4.2 p < 0.001‡
Age at first menstrual cycle 
(years)
13.1 ± 1.6 13.1 ± 1.6 13.1 ± 1.8 13.0 ± 1.4 p = 0.51‡
Menopausal status      
– Premenopausal 370 (41%) 179 (34%) 85 (45%) 106 (55%) p < 0.001†
– Postmenopausal 540 (59%) 349 (66%) 104 (55%) 87 (45%)  
Smoking related
– Pack-years – – – 19.3 ± 14.8 (190) –
– PY missing 3
– Time since cessation (years) – – 15.0 ± 10.2 (183) – –
– Time since cessation missing    6   
Alcohol consumption (g/day) 8.9 ± 12.3 7.0 ± 10.4 10.0 ± 12.2 12.9 ± 15.9 p < 0.001‡
Continuous variables are mean ± SD.
†p-value from Pearson’s χ2 test.
‡p-value from the Kruskal–Wallis test.
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Figure 1. Methylome-wide effect of tobacco smoking. (A, C, E) Manhattan plots showing the distribution of p-values of CpG sites 
associated with smoking exposure across chromosomes: (A) never-smokers versus current smokers, (C) former smokers versus current 
smokers, (E) never-smokers versus former smokers. The red horizontal line indicates the genome-wide significance threshold of 
p = 5 × 10-8, and the blue line is a threshold for suggestive association (p = 10-5). (B, D, F) Quantile-quantile (QQ) plots showing 
observed versus expected -log10(p-values) for the association between DNA methylation and smoking exposure (as a categorical 
variable): (B) never-smokers versus current smokers, (D) former smokers versus current smokers, (F) never-smokers versus former 
smokers.
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Differentially methylated CpG regional clusters 
in response to smoking: DMR analysis
Next, we investigated potential regional clustering of 
differential methylation to check whether neighbor-
ing differentially methylated CpG sites are correlated 
with each other. For this, we ran the same model used 
for identifying DMPs adjusted for latent variables by 
SVA, but accounting for correlations among proxi-
mal CpGs. This analysis revealed regionally clustered 
CpGs that were differentially methylated with smok-
ing status (Table 4). We identified eight DMRs associ-
ated with smoking status at a genome-wide family-wise 
empirical p-value [family-wise error rate (FWER)] 
<0.1, including six genes that were differentially meth-
ylated in the DMP analysis (ALPPL2, GFI1, MYO1G, 
AHRR, ZNF385D and IER3). The majority (6/8) of 
the DMRs showed lower methylation in current smok-
ers compared with never-smokers, while two (MYO1G 
and ZNF385D) showed higher methylation in current 
smokers (Table 4 & Figure 3A & B).
The identification of ALPPL2, GFI1, MYO1G, 
AHRR, ZNF385D and IER3 in both the DMP and 
DMR analyses substantiates their role in smoking-
related exposure. Our DMR analysis revealed two novel 
candidates: VTRNA2-1, an imprinted small noncod-
ing RNA, and ZFAND2A, also known as AIRAP. The 
effect of smoking-related methylation spans the entire 
VTRNA2-1 DMR, and the current smokers (n = 193) 
exhibited hypomethylation at the VTRNA2-1 DMR 
compared with the never-smokers (n = 528) (Figure 3C).
Most variable CpG methylation in response to 
smoking: MVP analysis
Differentially variable CpG sites have been reported to 
show increased variance in normal cells from people 
predisposed to neoplasia [36]. Through this study, we 
tried to better understand the smoking exposure asso-
ciated variability. We compared the differential vari-
ability between never-smokers and current smokers by 
DiffVar using a threshold of FDR ≤ 0.05. Our analysis 
revealed 14 differentially variable CpG sites associated 
with smoking exposure (Table 5). The 12 differentially 
variable sites with higher variability among current 
smokers compared with never-smokers are shown in 
Figure 4. Although we removed all potential CpG sites 
associated with SNPs in the initial quality control, we 
observed a site cg27126508 showing an SNP effect 
(Figure 4J). We then compared the DMP and MVP 
sets and found 50% (7/14) overlap, in which the top 
sites were common (Supplementary Figure 4).
Effect of smoking dosage on DNA methylation
We studied the effect of smoking dosage measured in 
pack-years (PY) on site-specific DNA methylation. We 
restricted this analysis to current smokers (n = 190) as 
we believed that the time since smoking cessation in for-
Table 2. Top five differentially methylated probes associated with smoking (never smokers vs 
current smokers).
CpG site Gene Region† p-value‡ Mean 
methylation (β 
values) in never 
smokers (SD)
Mean methylation 
(β values) in 
current smokers 
(SD)
Mean 
methylation 
difference 
(never-current)%
Hypermethylated in never smokers 
cg05575921 AHRR GB_SHO 3.40 × 10-109 0.85 (0.05) 0.67 (0.12) 17.6
cg23576855 AHRR GB_SHO 1.06 × 10-13 0.69 (0.19) 0.52 (0.17) 16.5
cg21566642 ALPPL2 IG_CGI 5.47 × 10-88 0.52 (0.06) 0.38 (0.08) 14.0
cg03636183 F2RL3 GB_SHO 9.12 × 10-65 0.70 (0.05) 0.58 (0.10) 12.0
cg06126421 IER3 DP_NC 4.14 × 10-54 0.76 (0.08) 0.65 (0.10) 11.5
Hypomethylated in never smokers
cg03274391 ZNF385D IG_SHO 3.26 × 10-6 0.57 (0.14) 0.68 (0.14) -10.8
cg23480021 ZNF385D IG_SHO 1.54 × 10-7 0.66 (0.14) 0.76 (0.13) -10.2
cg12803068 MYO1G GB_SHO 6.51 × 10-22 0.75 (0.12) 0.84 (0.11) -9.2
cg15693572 ZNF385D IG_SHO 1.65 × 10-6 0.56 (0.12) 0.65 (0.11) -9.1
cg23126342 PCDH9 GB_SHE 2.75 × 10-7 0.57 (0.09) 0.64 (0.10) -6.9
†Region denotes the relation of a CpG site to genes and CpG islands.
‡FDR corrected p-value.
CGI: CpG islands; DP: Distal promoter; GB:Gene body; IG: Intergenic; NC: Non-CpG islands; SD: Standard deviation; SHE: Shelves; 
SHO: Shores.
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mer smokers would dilute the effect of smoking dosage. 
For the analysis, we selected all 748 CpG sites found 
to be differentially methylated between never-smokers 
and current smokers. We calculated the Pearson correla-
tion coefficient between the PY values and the meth-
ylation values (β-values) of the CpG sites, and found 
that 153 CpG sites were significantly correlated with 
PY (Supplementary Table 5). A representative image of 
CpG sites with significant correlation to PY is shown 
in Figure 5A. CpGs hypomethylated in current smokers 
showed a decrease in methylation with increasing smok-
ing dosage (r range = -0.39 to -0.14), whereas CpGs 
hypermethylated in current smokers showed an increase 
in methylation with increasing smoking dosage (r range 
= 0.14–0.30). We observed a smoking dosage-depen-
dent change in the methylation of CpG sites (Figure 5B). 
The same trend was observed when we divided the cur-
rent smoker PY into quartiles (Q1: 1.0–8.1; Q2: 8.2–
16.4; Q3: 16.5–26.3 and Q4: 26.4–79.5) and compared 
them with never-smokers and former smokers. Figure 5C 
shows the effect of smoking dosage on one of the genes, 
IER3 (four CpGs), in which the methylation values 
decrease with increasing smoking dosage.
To investigate the effect of duration of smoking 
before smoking cessation, we did analyses by correlating 
time since smoking cessation in former smokers to DNA 
methylation changes. We found that the genes differ-
entially methylated in never-smokers relative to current 
smokers were also significantly associated with duration 
of smoking before cessation (Supplementary Figure 5).
Effect of time since smoking cessation on DNA 
methylation
Next, we investigated the reversibility of CpG methyl-
ation changes after smoking cessation by carrying out a 
longitudinal analysis in former smokers (n = 183). This 
analysis was done only on the probes that were signifi-
cantly altered by current smoking (current smokers vs 
former smokers, n = 163). We found that DMPs that 
were hypermethylated in current smokers relative to 
never-smokers showed decreased methylation with 
increasing time between smoking cessation and blood 
collection (Timq_smok) (negative correlation; r range 
= -0.16 to -0.27, n = 183; Figure 6A & B), sometimes 
returning to baseline levels (Figure 6C shows a repre-
sentative gene, IER3). In contrast, DMPs that were 
hypomethylated in smokers showed increased methyla-
tion with increasing Timq_smok (positive correlation; 
r range = 0.15–0.44, n = 183; Figure 6A & B).
To better understand the association between 
smoking-associated DNA methylation changes and 
the quartiles of Timq_smok, we focused on 37 DMPs 
Table 3. Novel differentially methylated probes associated with smoking (never smokers vs current 
smokers).
CpG site Gene Region† p-value‡ Mean 
methylation (β 
values) in never 
smokers (SD)
Mean 
methylation (β 
values) in current 
smokers (SD)
Mean 
methylation 
difference 
(never-current)%
Hypermethylated in never smokers 
cg22472290 ZNF577 PP_SHO 0.037257 0.72 (0.09) 0.68 (0.10) 3.8
cg16071219 LPAR6 GB_NC 0.001598 0.50 (0.06) 0.47 (0.06) 3.6
cg00008629 PTBP3 GB_SHO 0.006513 0.40 (0.09) 0.37 (0.10) 3.4
cg04224247 WWC3 NA 0.04738 0.57 (0.08) 0.54 (0.08) 3.1
cg24874254 PRDM1 PP_NC 0.009166 0.54 (0.08) 0.51 (0.09) 3.0
Hypomethylated in never smokers
cg24134897 TSPAN4 GB_SHO 1.72 × 10-5 0.75 (0.08) 0.79 (0.07) -3.9
cg02610360 TMEM136 GB_SHO 8.18 × 10-6 0.47 (0.07) 0.51 (0.07) -3.7
cg19925780 DPH5 IG_NC 8.00 × 10-5 0.78 (0.07) 0.81 (0.07) -3.5
cg05156137 RCAN1 PP_NC 0.045051 0.24 (0.06) 0.28 (0.06) -3.4
cg04387347 MIR5189 GB_CGI 2.51 × 10-8 0.25 (0.06) 0.28 (0.06) -3.4
cg01899620 MCF2L GB_SHO 0.000526 0.51 (0.07) 0.54 (0.07) -3.3
cg11028075 SORBS1 PP_NC 2.85 × 10-8 0.55 (0.06) 0.58 (0.06) -3.2
†Region denotes the relation of a CpG site to genes and CpG islands.
‡FDR corrected p-value.
CGI: CpG islands; GB: Gene body; IG: Intergenic; NA: Not available; NC: Non-CpG islands; PP: Proximal promoter; SD: Standard deviation; 
SHO: Shores.
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Figure 2. Functional distribution of smoking-associated CpG sites. (A) Distribution of smoking exposure-
associated CpGs (never-smokers vs current smokers) relative to CGI (i.e., islands, shores, shelves). The distribution 
of all Illumina HM450K array probes is shown for comparison. (B) The distribution of differentially methylated 
CpGs based on distance from the TSS. The distribution of all Illumina HM450K array probes based on distance from 
the TSS is shown for comparison. 
CGI: CpG islands; DMP: Differentially methylated probe; TSS: Transcription start site.
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that were significantly correlated with Timq_smok 
(p-value < 0.05; Supplementary Table 6). We studied 
these sites (n = 37) in detail to discern the methylation 
dynamics and reversibility, and compared the methyla-
tion levels between never-smokers and former smokers 
in quartiles of time of cessation: Q1 (0.5–6.5 years), 
Q2 (6.6–14 years), Q3 (14.1–22 years) and Q4 (22.1–
42.5 years). Compared with never-smokers, methyla-
tion levels of 15 CpG sites (Table 6 & Figure 6D), six 
CpG sites (cg00310412, cg03636183, cg05575921, 
cg06126421, cg11207515 and cg14817490), and four 
CpG sites (cg01940273, cg05951221, cg011554391 
and cg21566642) were significantly different in Q1, 
Q2 and Q3 of former smokers, respectively. No DMPs 
were different between never-smokers and Q4 of for-
mer smokers, indicating that DNA methylation for 
those 37 DMPs almost reaches the baseline (levels in 
never-smokers) 22.1 years after smoking cessation.
Discussion
We performed a genome-wide methylation study to 
investigate the effect of smoking exposure on DNA 
methylation using baseline blood samples collected 
in a prospective cohort. We identified 748 CpG sites 
that were differentially methylated between current 
smokers and never smokers (FDR <0.05). Most of the 
differentially methylated sites in our study were simi-
lar to those identified in previous studies on maternal 
smoking [12,16,37–40] and adult smoking [10,13–15,41–45], 
strengthening the view that alterations due to smok-
ing exposure could be detected in the blood irrespec-
tive of the study population and sex. Thus, blood-
based methylation markers are a robust measure of 
smoking exposure. However, unlike any of the previ-
ous studies, we carried out new analyses, which led to 
the identification of regional alterations and the vari-
ability of DNA methylation due to smoking exposure. 
Furthermore, 12 of the 748 differentially methylated 
sites (≥3% methylation difference) remain unre-
ported to date: cg22472290 (ZNF577), cg16071219 
(LPAR6 ), cg00008629 (PTBP3), cg04224247 
(WWC3), cg24874254 (PRDM1), cg24134897 
(TSPAN4), cg02610360 (TMEM136 ), cg19925780 
(DPH5), cg05156137 (RCAN1), cg04387347 
(MIR5189), cg01899620 (MCF2L) and cg11028075 
(SORBS1).
Although the functional impact of differential 
methylation in the specific genes associated with smok-
ing status (identified in our study and several recent 
studies by other groups) remains to be established, 
identification of AHHR and ALPPL2 makes sense 
biologically. The AHHR gene is part of the aryl hydro-
HM450
CGI-centric distribution
DMPs
Distribution of DMPs related to TSS
50 50 6040 4030 3020 2010 10TSS
DMPs (%)
HM450
DMPs
Island
Open sea
Shelf
Shore
Feature
0–1 kb
1–3 kb
3–5 kb
5–10 kb
10–100 kb
>100 kb
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carbon pathway that metabolizes cigarette smoke com-
ponents [46], and its hypomethylation was found to be 
associated with lung cancer risk [47]. The ALPPL2 gene 
is responsible for dephosphorylation of various mol-
ecules (including proteins, nucleotides or alkaloids) 
and ALPPL2 enzyme levels were found increased up to 
tenfold in cigarette smokers and patients with different 
cancers [48,49].
An interesting finding from our study was the hyper-
methylation of cg00008629 (PTBP3) in current smok-
ers compared with never-smokers. PTBP3 (also known 
as regulator of differentiation 1, or ROD1) encodes an 
RNA-binding protein that plays a role in the regulation 
of cell proliferation and differentiation and is presum-
ably expressed in cells of the hematopoietic system [50]. 
The CpG site (cg00008629) is located on the gene 
body, which is generally associated with increased gene 
expression [51] and, considering this, we presume that 
methylation of PTBP3 would lead to increased tran-
scriptional activity in never-smokers. PTBP3 has been 
reported to bind and post-transcriptionally regulate 
approximately 13,000 genes, including those related 
to the differentiation and proliferation of cells [52]. We 
believe that this homeostatic control of post-transcrip-
tional regulation may be lost due to smoking exposure, 
although the mechanisms and underlying pathways 
remain to be elucidated.
Regional alterations in VTRNA2-1 (nc886) and 
ZFAND2A related to active smoking exposure are 
novel. VTRNA2-1 is an imprinted small noncoding 
RNA that is a putative tumor suppressor and a modula-
tor of innate immunity. A previous report by Treppen-
dahl et al. indicated that VTRNA2-1 may be polymor-
phically imprinted [53], although our recent findings 
suggest that VTRNA2-1 is not regulated by cis genetic 
variation but is affected by the maternal environment 
around the time of conception, occurs systemically, 
and is stable over many years [54]. Our results point 
to a regional loss of imprinting of VTRNA2-1 in cur-
rent smokers compared with never-smokers, showing 
that active smoking exposure could lead to the regional 
alteration of noncoding RNAs.
ZFAND2A behaves as a canonical heat shock gene, 
whose expression is strictly controlled by HSF1 in a 
temperature-dependent fashion [55]. It is an HSF1 
target and is transcriptionally regulated by tempera-
ture [55]. To date, there are no reports linking methyla-
tion of ZFAND2A and active smoking exposure. More 
studies are needed to elucidate the functional relevance 
of the regional alterations mediated by smoking.
The fact that seven of the top DMPs (cg05575921, 
cg18146737, cg03636183, cg21566642, cg18316974, 
cg05951221 and cg14817490) were found within 
genes that show variable methylation in response to T
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Figure 3. Methylome-wide regional alterations (see facing page). (A) Line plot showing ALPPL2 hypomethylated 
in current smokers compared with never and former smokers. (B) Line plot showing MYO1G hypermethylated in 
current smokers compared with never and former smokers. X-axis shows the CpG sites represented by the gene 
and Y-axis shows the methylation value. (C) Regional alteration of VTRNA2-1 in response to smoking exposure. 
Fifteen CpGs mapping to the VTRNA2-1 locus are shown. The box highlights nine CpGs corresponding to the 
imprinted DMR. X-axis shows the CpG sites represented by VTRNA2-1 and Y-axis shows the methylation value.
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smoking exposure is consistent with the notion that 
an interplay exists between different epigenetic regula-
tion mechanisms, which may exhibit different modes 
of alteration in response to the same exposure (smok-
ing), and suggests that the combination of distinct dif-
ferentially and variably methylated loci may have an 
important role in smoking-related exposures.
Seven of the most variable CpG sites have not 
been reported previously (cg17524265, cg27326062, 
cg27126508, cg12868738, cg04654261, cg00559054 
and cg19160130). For instance, it is worth noting that 
one of the CpGs (cg17524265) on the gene NAPRT 
(nicotinic acid phosphoribosyltransferase) is more vari-
able in never-smokers compared with current smokers. 
This variability may have some link to nicotinic acid 
metabolism in smokers, although further mechanistic 
and validation studies are needed.
With respect to the effect of smoking dosage and 
smoking duration as well as of the time since smoking 
cessation, we found that CpGs that are hypermeth-
ylated in current smokers showed decreased meth-
ylation with longer time since smoking cessation and 
increased methylation with increasing smoking dosage 
(PY). In contrast, CpGs that are hypomethylated in 
current smokers showed increased methylation with 
longer time since smoking cessation and decreased 
methylation with increasing smoking dosage. Our 
findings point to a strong influence of smoking dos-
age and time since smoking cessation in line with a 
recent study [14]. Interestingly, for four CpG sites 
[cg01940273 (ALPPL2), cg05951221 (ALPPL2), 
cg11554391 (AHRR) and cg21566642 (ALPPL2)], 
methylation levels did not decrease to the baseline lev-
els of never-smokers even 14.1–22 years after smok-
ing cessation, and these CpGs may serve as markers 
for follow-up of former smokers for secondary cancer 
prevention. Previous studies also identified elevated 
serum levels and differential methylation of ALPPL2 
in response to smoking [13–14,49], although no studies 
have looked at the response of ALPPL2 to smoking 
cessation. All the CpG sites related to the ALPPL2 
gene are located in an intergenic CpG island, hint-
ing at transcriptional initiation activity, as previously 
reported [56]. Based on our results and previously pub-
lished literature, the methylation levels of the ALPPL2 
and AHRR genes could be used as markers of time 
since smoking cessation and of lifetime exposure to 
tobacco smoke.
Our study has many strengths, including a large 
sample size (n = 910), a comprehensive characteriza-
tion of smoking-associated DNA methylation changes 
at site-specific, regional and variable positions, as well 
as an assessment of methylation markers for smoking 
dosage, smoking duration and reversibility after smok-
ing cessation. A possible limitation of this study is the 
self-reported smoking information from the partici-
pants, which is sometimes under-reported [57]. Another 
possible limitation of our study is that we combined 
prediagnostic blood samples from prospective breast 
cancer cases and controls for the analysis. We addressed 
this issue by carrying out control-only and cases-only 
analyses to assess the effect of smoking on DNA meth-
ylation, revealing results similar to those obtained by 
combining both categories (Supplementary Figure 6).
It is noteworthy that we observed relatively small 
but significant differences in methylation of specific 
CpG sites and gene loci associated with smoking sta-
tus. This is consistent with a number of recent studies 
that interrogated DNA methylation profiles in normal 
(nontumor) tissues (such as peripheral blood). Con-
sidering a robust platform applied and large number of 
samples analyzed, our study was sufficiently powered 
for detecting small differences in DNA methylation 
Table 5. Top differentially variable probes associated with 
smoking (never smokers vs current smokers).
CpG site Gene DiffLevene p-value†
cg05575921 AHRR 0.408544 9.97 × 10-27
cg18146737 GFI1 0.529640 5.38 × 10-10
cg03636183 F2RL3 0.191574 1.73× 10-8
cg21566642 ALPPL2 0.152698 1.12 × 10-6
cg18316974 GFI1 0.282920 0.000268
cg05951221 ALPPL2 0.13123 0.000463
cg14817490 AHRR 0.150597 0.001486
cg17524265 NAPRT -0.18824 0.005191
cg27326062 LINC01205 1.265635 0.006142
cg27126508 COL23A1 0.639640 0.007965
cg12868738 ZNF212 0.467374 0.018975
cg04654261 STK19 0.171126 0.034163
cg00559054 SSR3 0.196784 0.043037
cg19160130 RAB30 -0.168180 0.043037
†FDR-corrected p-value.
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Figure 4. Most variable probes in response to smoking exposure. (A–l) Scatter plots showing the 12 most variable 
probes in the indicated genes in response to smoking exposure (never-smokers vs current smokers). The x axis 
shows the two categories, never-smokers and current smokers, and the y axis shows the methylation value 
(β-value). Note that current smokers show more variability compared with never-smokers, indicating that smoking 
may be responsible for the interindividual variability in DNA methylation patterns.
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Figure 5. Effect of smoking dosage on DNA methylation. (A) Correlation plots showing the effect of smoking 
dosage measured in pack-years (PY) on DNA methylation across the indicated CpG sites. (B) Line plot showing 
the extent of methylation changes across six CpG sites in response to smoking dosage (PY). (C) An example shows 
alterations in methylation of the IER3 gene in response to PY quartiles (Q1: 1.0–8.1; Q2: 8.2–16.4; Q3: 16.5–26.3 
years; and Q4: 26.4–79.5 years). The x axis shows the groups of samples, and the y axis shows the methylation 
values. CpG1: cg06126421, CpG2: cg14753356, CpG3: cg15342087, CpG4: cg24859433.
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Figure 6. Effect of time since smoking cessation on DNA methylation. (A) Correlation plot showing the effect of time since 
smoking cessation on DNA methylation across the indicated CpG sites. (B) Line plot showing the extent of methylation changes 
across four CpG sites which remained differentially methylated between never smokers and former smokers up to 14.1–22 years 
after smoking cessation. (C) An example shows the effect of time since cessation on DNA methylation of the IER3 gene based on 
quartiles of time since cessation; the x axis shows the sample groups, and the y axis shows the methylation values. CpG1: cg06126421, 
CpG2: cg14753356, CpG3: cg15342087, CpG4: cg24859433. (D) Heat map showing methylation dynamics and reversibility at 37 CpG 
sites that were significantly correlated with time between smoking cessation and blood collection (Timq_smok). We compared the 
methylation levels at these sites between never-smokers and Timq_smok in former smokers (Q1: 0.5–6.5 years; Q2: 6.6–14 years; 
Q3: 14.1–22 years; and Q4: 22.1–42.5 years).
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and a high level of concordance between the smoking-
associated methylation changes identified in our study 
and those in other groups, we think that our findings 
are robust and are highly unlikely to be a result of 
confounding and biases. Considering a binary type of 
methylation data (a given cytosine can be methylated 
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or not at the level of single cells) [58], small methyla-
tion changes in complex tissues, such as white blood 
cells, may reflect substantial changes in specific sub-
population. While purification of blood cell subtypes 
for epigenetic analyses in large molecular epidemiol-
ogy studies is not feasible, a detailed follow-up study 
using in vitro and in vivo models should address func-
tional implications of smoking-induced methylation 
changes.
Through the present study, we have comprehen-
sively cataloged the smoking-associated DNA meth-
ylation alterations (DMPs, DMRs and MVPs) in a 
large prospective study. We have reported several novel 
epigenetic biomarkers of smoking, encompassing 12 
novel DMPs, two coding and noncoding DMRs and 
seven MVPs. Furthermore, we have identified methyl-
ation biomarkers that may be used for follow-up of for-
mer smokers and to assess lifetime exposure to tobacco 
smoke. These findings may have important contribu-
tions to the understanding of the mechanistic biology 
and reversibility effects in response to smoking and 
may be coupled with existing biomarkers of smoking.
Conclusion
The present study examined the potential of DNA 
methylation changes in prediagnostic peripheral blood 
samples as a marker of exposure to tobacco smoke in a 
large multinational cohort of the EPIC study, using the 
Illumina HumanMethylation 450K BeadChip array. 
We identified a total of 748 CpG sites that were differ-
entially methylated between baseline smokers and non-
smokers. While many differentially methylated sites 
included CpG sites from genes identified in previous 
studies, we identified novel CpG sites associated with 
smoking. Dimension reduction approaches further 
revealed novel regionally clustered CpGs associated 
with active smoking exposure. Importantly, we found 
a marked reversibility of methylation changes after 
smoking cessation, although specific genes remained 
differentially methylated up to 22 years after cessation.
Thus, our study has comprehensively cataloged 
the smoking-associated DNA methylation alterations 
including newly identified coding and noncoding 
genes associated with active smoking. Our study also 
showed that prediagnostic smoking-related epigenetic 
alterations in human blood cells are reversible after 
smoking cessation, consistent with the known cancer 
risk reduction.
Future perspective
We envisage that the markers of smoking-related meth-
ylation changes identified through our study could be 
used to assess the lifetime exposure to smoking in cur-
rent smokers and more importantly to follow former 
smokers. Thus, our study provides interesting targets 
for smoking-related secondary cancer prevention. 
Future studies to understand the mechanistic link 
between our findings and validation of our findings in 
other study cohorts are warranted.
Supplementary data
To view the supplementary data that accompany this paper 
please visit the journal website at: www.futuremedicine.com/
doi/full/10.2217/epi-2016-0001
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Executive summary
•	 Using a large prospective study, our study has comprehensively cataloged the smoking-associated DNA 
methylation alterations including novel regionally altered coding and noncoding genes.
•	 We identified a total of 748 CpG sites that were differentially methylated between smokers and nonsmokers, 
including novel regionally clustered CpGs associated with active smoking exposure.
•	 We found a marked reversibility of methylation changes after smoking cessation and discrete genes that 
remained differentially methylated decades after cessation.
•	 Our study revealed that prediagnostic smoking-related epigenetic alterations in human blood cells are 
reversible after smoking cessation, consistent with the known cancer risk reduction.
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